Added to YB: 2026-01-07
Pitch date: 2025-12-03
NVO [bullish]
Novo Nordisk A/S
+20.21%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.5T
Pitch Price
DKK 304.80
Price Target
180.00 (-51%)
Dividend
3.36%
EV/EBITDA
9.64
P/E
14.86
EV/Sales
5.10
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: From Insulin Giant to Global Metabolic Infrastructure
NVO: facing unprecedented competition - Lilly advancing faster w/ superior next-gen efficacy; Pfizer's Metsera acquisition intensifies landscape. Bull case: oral GLP-1 unlock, $330B+ revenue, 84%+ gross margins, massive CapEx expansion creating multi-decade platform. Bear case: competitive displacement, manufacturing bottlenecks. DCF targets $165-180 base case. Execution-critical investment w/ asymmetric outcomes.
Read full article (22 min)